GMAB - Genmab launches late-stage tisotumab study in cervical cancer

Genmab ([[GMAB]] -0.4%) announces initiation of innovaTV 301 Phase 3 trial evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer who have received one or two prior lines of systemic therapy. The 482-subject study will evaluate efficacy of tisotumab compared with physician’s choice single agent chemotherapy. Primary endpoint will be overall survival.Tisotumab vedotin is an investigational antibody-drug conjugate. It is being co-developed by Genmab and Seagen, under an agreement in which the companies share all costs and profits for the product on a 50:50 basis.

For further details see:

Genmab launches late-stage tisotumab study in cervical cancer